<?xml version='1.0' encoding='utf-8'?>
<document id="28457720"><sentence text="Quantitative Analysis of the Transporter-Mediated Drug-Drug Interaction Between Atorvastatin and Rifampicin Using a Stable Isotope-IV Method."><entity charOffset="80-92" id="DDI-PubMed.28457720.s1.e0" text="Atorvastatin" /><entity charOffset="97-107" id="DDI-PubMed.28457720.s1.e1" text="Rifampicin" /><pair ddi="false" e1="DDI-PubMed.28457720.s1.e0" e2="DDI-PubMed.28457720.s1.e0" /><pair ddi="false" e1="DDI-PubMed.28457720.s1.e0" e2="DDI-PubMed.28457720.s1.e1" /></sentence><sentence text="This study aims to investigate the drug-drug interactions (DDIs) between orally administered atorvastatin (ATV) and rifampicin (RIF) in rats"><entity charOffset="93-105" id="DDI-PubMed.28457720.s2.e0" text="atorvastatin" /><entity charOffset="107-110" id="DDI-PubMed.28457720.s2.e1" text="ATV" /><entity charOffset="116-126" id="DDI-PubMed.28457720.s2.e2" text="rifampicin" /><entity charOffset="128-131" id="DDI-PubMed.28457720.s2.e3" text="RIF" /><pair ddi="false" e1="DDI-PubMed.28457720.s2.e0" e2="DDI-PubMed.28457720.s2.e0" /><pair ddi="false" e1="DDI-PubMed.28457720.s2.e0" e2="DDI-PubMed.28457720.s2.e1" /><pair ddi="false" e1="DDI-PubMed.28457720.s2.e0" e2="DDI-PubMed.28457720.s2.e2" /><pair ddi="false" e1="DDI-PubMed.28457720.s2.e0" e2="DDI-PubMed.28457720.s2.e3" /><pair ddi="false" e1="DDI-PubMed.28457720.s2.e1" e2="DDI-PubMed.28457720.s2.e1" /><pair ddi="false" e1="DDI-PubMed.28457720.s2.e1" e2="DDI-PubMed.28457720.s2.e2" /><pair ddi="false" e1="DDI-PubMed.28457720.s2.e1" e2="DDI-PubMed.28457720.s2.e3" /><pair ddi="false" e1="DDI-PubMed.28457720.s2.e2" e2="DDI-PubMed.28457720.s2.e2" /><pair ddi="false" e1="DDI-PubMed.28457720.s2.e2" e2="DDI-PubMed.28457720.s2.e3" /></sentence><sentence text=" The isotope-IV method was used for the analysis of the increased systemic exposure (AUCpo) of ATV, in which a small amount of deuterium-labeled ATV (ATV-d5) was intravenously injected after oral administration of ATV"><entity charOffset="127-136" id="DDI-PubMed.28457720.s3.e0" text="deuterium" /><entity charOffset="95-103" id="DDI-PubMed.28457720.s3.e1" text="ATV" /><entity charOffset="145-153" id="DDI-PubMed.28457720.s3.e2" text="ATV" /><entity charOffset="150-158" id="DDI-PubMed.28457720.s3.e3" text="ATV" /><entity charOffset="214-222" id="DDI-PubMed.28457720.s3.e4" text="ATV" /><pair ddi="false" e1="DDI-PubMed.28457720.s3.e1" e2="DDI-PubMed.28457720.s3.e1" /><pair ddi="false" e1="DDI-PubMed.28457720.s3.e1" e2="DDI-PubMed.28457720.s3.e0" /><pair ddi="false" e1="DDI-PubMed.28457720.s3.e1" e2="DDI-PubMed.28457720.s3.e2" /><pair ddi="false" e1="DDI-PubMed.28457720.s3.e1" e2="DDI-PubMed.28457720.s3.e3" /><pair ddi="false" e1="DDI-PubMed.28457720.s3.e1" e2="DDI-PubMed.28457720.s3.e4" /><pair ddi="false" e1="DDI-PubMed.28457720.s3.e0" e2="DDI-PubMed.28457720.s3.e0" /><pair ddi="false" e1="DDI-PubMed.28457720.s3.e0" e2="DDI-PubMed.28457720.s3.e2" /><pair ddi="false" e1="DDI-PubMed.28457720.s3.e0" e2="DDI-PubMed.28457720.s3.e3" /><pair ddi="false" e1="DDI-PubMed.28457720.s3.e0" e2="DDI-PubMed.28457720.s3.e4" /><pair ddi="false" e1="DDI-PubMed.28457720.s3.e2" e2="DDI-PubMed.28457720.s3.e2" /><pair ddi="false" e1="DDI-PubMed.28457720.s3.e2" e2="DDI-PubMed.28457720.s3.e3" /><pair ddi="false" e1="DDI-PubMed.28457720.s3.e2" e2="DDI-PubMed.28457720.s3.e4" /><pair ddi="false" e1="DDI-PubMed.28457720.s3.e3" e2="DDI-PubMed.28457720.s3.e3" /><pair ddi="false" e1="DDI-PubMed.28457720.s3.e3" e2="DDI-PubMed.28457720.s3.e4" /></sentence><sentence text=" By assuming ATV-d5 showed same pharmacokinetic properties with ATV, this method enabled to calculate the systemic clearance (CLtot) and the oral bioavailability (Foral) of ATV for each individual rat in a single experiment"><entity charOffset="13-15" id="DDI-PubMed.28457720.s4.e0" text="ATV" /><entity charOffset="64-66" id="DDI-PubMed.28457720.s4.e1" text="ATV" /><entity charOffset="173-175" id="DDI-PubMed.28457720.s4.e2" text="ATV" /><pair ddi="false" e1="DDI-PubMed.28457720.s4.e0" e2="DDI-PubMed.28457720.s4.e0" /><pair ddi="false" e1="DDI-PubMed.28457720.s4.e0" e2="DDI-PubMed.28457720.s4.e1" /><pair ddi="false" e1="DDI-PubMed.28457720.s4.e0" e2="DDI-PubMed.28457720.s4.e2" /><pair ddi="false" e1="DDI-PubMed.28457720.s4.e1" e2="DDI-PubMed.28457720.s4.e1" /><pair ddi="false" e1="DDI-PubMed.28457720.s4.e1" e2="DDI-PubMed.28457720.s4.e2" /></sentence><sentence text=" RIF was orally pretreated to rats to inhibit the organic anion transporting polypeptide 1B1 (OATP1B1)"><entity charOffset="1-3" id="DDI-PubMed.28457720.s5.e0" text="RIF" /></sentence><sentence text=" From the analysis using pharmacokinetic parameters in each rat, it was revealed that the AUCpo of ATV increased depending on the plasma level of RIF, showing that the interindividual difference in the absorption of RIF caused the large variability in the extent of DDI"><entity charOffset="99-101" id="DDI-PubMed.28457720.s6.e0" text="ATV" /><entity charOffset="146-148" id="DDI-PubMed.28457720.s6.e1" text="RIF" /><entity charOffset="216-218" id="DDI-PubMed.28457720.s6.e2" text="RIF" /><pair ddi="false" e1="DDI-PubMed.28457720.s6.e0" e2="DDI-PubMed.28457720.s6.e0" /><pair ddi="false" e1="DDI-PubMed.28457720.s6.e0" e2="DDI-PubMed.28457720.s6.e1" /><pair ddi="false" e1="DDI-PubMed.28457720.s6.e0" e2="DDI-PubMed.28457720.s6.e2" /><pair ddi="false" e1="DDI-PubMed.28457720.s6.e1" e2="DDI-PubMed.28457720.s6.e1" /><pair ddi="false" e1="DDI-PubMed.28457720.s6.e1" e2="DDI-PubMed.28457720.s6.e2" /></sentence><sentence text=" Furthermore, it was indicated that not only the decrease in CLtot but also the increase in Foral caused the significant increase in the AUCpo of ATV"><entity charOffset="146-148" id="DDI-PubMed.28457720.s7.e0" text="ATV" /></sentence><sentence text=" In conclusion, the isotope-IV method possesses various advantages over the conventional method for the analysis of DDIs which affects both absorption and elimination processes of oral drugs" /><sentence text="" /></document>